Volume 15, Number 3 (Apr 2024)

Editorial

Shaping the Future of Oncology at JADPRO Live 2023

Last fall, the 2023 JADPRO Live conference welcomed more than 1,500 in-person attendees and 200 virtual attendees. Sessions took place at the Orlando World Center Marriott from November 9 through 12. Select CE-accredited sessions were li...

April 17, 2024

Meeting Report

Staying Abreast of New Biomarkers in Hematology/Oncology

There has been an increasing number of approvals for targeted therapies in oncology in the past decade, changing the treatment paradigm for many solid tumors and hematologic malignancies. At JADPRO Live 2023, presenters provided an in-de...

April 17, 2024

Meeting Report

2022–2023 Drug Updates in Solid Tumors

At JADPRO Live 2023 in Orlando, Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, briefed advanced practitioners on key US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Holle described indications, mechanisms of actio...

April 17, 2024

Meeting Report

2022–2023 Drug Updates in Hematologic Malignancies

At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring an...

April 17, 2024

Meeting Report

2022–2023 Drug Updates: Investigational Therapeutics in the Pipeline

During JADPRO Live 2023, Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Cuellar highlighted new drug classes, novel mechanisms of action, and safety profiles...

April 17, 2024

Meeting Report

Improving Outcomes for Women With Metastatic HER2-Positive and HER2-Low Breast Cancer

At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status,...

April 17, 2024

Meeting Report

Advancing Precision-Targeted Treatment for Patients With Metastatic Non–Small Cell Lung Cancer

At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecu...

April 17, 2024

Meeting Report

Optimizing the Care of Patients With Colorectal Cancer in Clinical Practice

At JADPRO Live 2023, presenters emphasized the importance of increasing colorectal cancer screening in high-risk groups, reviewed guidelines in the adjuvant and metastatic setting, and outlined clinical and molecular profiles to consider...

April 17, 2024

Meeting Report

Improving Prostate Cancer Patient Care in the Clinical Setting

At JADPRO Live 2023 in Orlando, presenters provided an overview of best practices in the diagnosis, classification, and management of patients with localized and metastatic prostate cancer. They covered selecting appropriate therapies ba...

April 17, 2024

Meeting Report

Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs

At JADPRO Live 2023 in Orlando, presenters discussed selecting treatment regimens for newly diagnosed and relapsed or refractory multiple myeloma. They also provided insights on comprehensive care centered around patient preferences, tre...

April 17, 2024